Processa Pharmaceuticals acquires Vidya Therapeutics, lines up $200 million private placement
The deal brings BTK inhibitor VT-7208 into Processa's pipeline and is meant to fund operations into the second half of 2029.
SEC filing
Latest
Wednesday, July 29
Silexion activates first site for SIL204 pancreatic cancer trial in Israel
Tel Aviv Sourasky Medical Center becomes the first active site in Silexion's Phase 2/3 study of SIL204, with patient screening expected to start soon.
SEC filing
Eton Pharmaceuticals submits FDA supplement to expand KHINDIVI to younger children
The company filed a Prior Approval Supplement seeking to lower KHINDIVI's approved age from five years, with a possible decision in the first half of 2027.
SEC filing
Lancet publishes Capricor's HOPE-3 data as FDA review continues
The peer-reviewed publication comes with a revised LVEF statistical result and disclosure of an FDA inspection finding tied to the Deramiocel trial.
SEC filing
J&J closes $1 billion acquisition of Firefly Bio
The deal adds Firefly's degrader antibody conjugate platform aimed at KRAS-driven cancers and will cut J&J's 2026 adjusted EPS by about $0.46.
SEC filing
LB Pharmaceuticals sets $150 million private placement of stock and warrants
The neuromedicines company will sell shares and pre-funded warrants to institutional investors to expand its LB-102 pipeline into new indications.
SEC filing
AbCellera to lead T-cell engager discovery for Vertex under new autoimmune disease pact
Vertex will fund R&D and hold development and commercialization rights, while AbCellera receives upfront payments and is eligible for milestones and royalties.
SEC filing
Teva posts Q2 2026 GAAP loss on Emalex charge, raises innovative brand outlook
Teva reported a $576 million net loss tied to the Emalex acquisition and ecopipam NDA filing, while raising its 2026 revenue outlook for AUSTEDO, AJOVY and UZEDY.
SEC filing
Adaptive Biotechnologies posts Q2 2026 revenue growth, plans Immune Medicine separation
The company raised full-year MRD revenue guidance and disclosed a $345 million convertible notes deal alongside a leadership change for co-founder Harlan Robins.
SEC filing
OS Therapies terminates $18 million at-the-market stock sale agreement
The company ended its ATM facility with B. Riley Securities and JonesTrading, having sold only a small fraction of the authorized amount.
SEC filing
Biogen posts Q2 2026 results, sets five late-stage readouts over next four quarters
The company narrowed its underlying non-GAAP EPS guidance upward while absorbing Apellis-related dilution, and flagged upcoming litifilimab, felzartamab and zorevunersen data.
SEC filing
Ionis posts Q2 2026 results, flags second-half pipeline milestones
TRYNGOLZA and DAWNZERA launches build early momentum as Ionis awaits zilganersen approval, an Lp(a) outcomes readout, and a hepatitis B launch.
SEC filing
Onconetix arranges $30.25 million PIPE financing and $750 million equity line
The company entered agreements on July 28, 2026 for a Series F preferred stock sale and a large committed equity facility, both disclosed in an 8-K filed with the SEC.
SEC filing
Xencor to receive $105 million from Alexion to settle Ultomiris royalty dispute
The payment resolves a dispute over U.S. royalties on Ultomiris, with Alexion ending U.S. royalty obligations while ex-U.S. royalties continue unchanged.
SEC filing
Corcept raises 2026 revenue guidance to $1.1-$1.2 billion after Lifyorli launch quarter
The company reported second-quarter revenue of $256.1 million, driven by Korlym and a new Lifyorli launch, and outlined multiple near-term regulatory and trial milestones.
SEC filing
TuHURA Biosciences draws $1.5 million more under Parkview credit facility
The July 28, 2026 draw comes under a revolving loan agreement with Parkview Holdings One LLC that can provide up to $50 million.
SEC filing
PolyPid's D-PLEX100 NDA accepted with priority review, PDUFA date set for November 2026
FDA acceptance triggers a $15 million milestone payment from partner Azurity, and PolyPid says review is now on track to finish about three months sooner than expected.
SEC filing
Inovio discloses preliminary cash of $36.7 million as of June 30, 2026
The disclosure came in an 8-K filed alongside a prospectus supplement dated July 29, 2026, with no operating or pipeline updates included.
SEC filing
Pfizer registers Phase 3 trials in alopecia areata and chronic migraine; two Phase 1 studies open
CDT Equity issues 32,110 shares to consultant for services
CDT Equity Inc. disclosed a July 24, 2026 stock issuance to a service provider, made without registering the shares under securities law.
SEC filing
Humacyte posts trauma trial results, registers new Phase 2a coronary CTEV study for CABG
Filana Therapeutics still under FDA clinical hold on simufilam trial, reports Q2 2026 results
The company said it continues to work with the FDA to resolve the hold as it heads into the TSC World Conference, while cash fell to $82.7 million.
SEC filing
Inhibikase swaps RA Capital's common shares for pre-funded warrant
Inhibikase Therapeutics exchanged 18,030,000 shares held by RA Capital for a pre-funded warrant covering the same number of shares.
SEC filing
Tuesday, July 28
Yarrow Bioscience details Phase 2a/2b trial design, merger share counts after VYNE closing
New 8-K filing adds trial specifics, share totals, and merger mechanics for the combined company now trading as YARW.
SEC filing
Standard BioTools agrees to sell Mass Cytometry unit, gets $30M Illumina payout
The deal with Multiplex Bio is pending stockholder approval and expected to close alongside the Treeline merger by year-end 2026.
SEC filing
Hansoh's Ris-Rez hits PFS endpoint in second phase III osteosarcoma trial
GSK's licensor Hansoh Pharma reported that ARTEMIS-011 met its primary endpoint in relapsed osteosarcoma, adding to prior positive lung cancer data.
SEC filing
Kiniksa raises 2026 ARCALYST guidance, advances KPL-387 into Phase 3 pericarditis trial
The company reported Q2 2026 ARCALYST revenue of $243.6 million and said Phase 2 data on KPL-387 supported starting the pivotal PASTORALE trial, which is now enrolling patients.
SEC filing
Alterity registers open-label extension for ATH434 in French MSA patients
Compass Therapeutics posts Phase 2 results for CTX-009 in metastatic colorectal cancer trial
Incyte raises 2026 sales guidance, adds ten data readouts, closes Vega deal
The company lifted full-year net sales and expense guidance and outlined ten clinical readouts for the second half of 2026, including four registrational trials.
SEC filing
Repligen raises 2026 guidance after 13% organic revenue growth in Q2
The bioprocessing company also disclosed a definitive agreement to acquire BioLife Solutions as it lifted its full-year revenue and earnings outlook.
SEC filing
Yale registers Phase 2 trial of Tonix's TNX-1900 for pituitary surgery pain
Phibro Animal Health declares quarterly dividend of $0.12 per share
The board approved a payout for both share classes, payable in September to holders of record in early September.
SEC filing
Nasus Pharma names Brendan P. O'Grady CEO, succeeding Dan Teleman
The intranasal drug developer said O'Grady will focus on NS002 commercialization ahead of a planned pivotal trial and 2027 data readout.
SEC filing
Bicara Therapeutics names two new directors as Mazumdar-Shaw exits board
The clinical-stage oncology company added Jeremy Bender and Christy Oliger to its board while founding director Kiran Mazumdar-Shaw resigned.
SEC filing
IQVIA raises 2026 guidance after strong second-quarter bookings and revenue growth
The company posted 8.7% revenue growth and record R&D Solutions bookings, then raised its full-year revenue, EBITDA and EPS guidance.
SEC filing
Jupiter Neurosciences sells $3.6M in stock to Yorkville under equity line
Between May 14 and July 24, 2026, Jupiter Neurosciences issued 11,470,000 shares to Yorkville under its standby equity purchase agreement, lifting total shares outstanding to 56,520,143.
SEC filing
Sonavex files Form D for $15 million equity offering
The Baltimore biotech has raised roughly $3.1 million so far from five investors, with over $11.8 million still to be sold.
SEC filing
Entera Bio raises $275 million in private placement led by BVF Partners funds
The Israeli drug developer will use the proceeds to launch a phase 3 osteoporosis trial of EB613 after closing the deal on July 28, 2026.
SEC filing
NRC Health posts 11% TRCV growth in Q2 2026, but net loss on stock vesting costs
NRC Health reported total recurring contract value of $151.9 million, up 11% year over year, alongside a GAAP net loss tied to one-time stock vesting and bonus costs.
SEC filing
Trial registered for tafasitamab plus rituximab in newly diagnosed follicular lymphoma
Relmada names Bipin Dalmia as Chief Business Officer
The clinical-stage biotech brought on the former Ferring uro-oncology executive to help guide strategy for its bladder cancer therapy NDV-01.
SEC filing
Alkermes names Blair Jackson CEO, effective August 1, as pipeline milestones near
Richard Pops steps down as CEO to remain Chairman while Alkermes awaits ADHD data for ALKS 7290 and year-end results from its alixorexton hypersomnia study.
SEC filing
Gland Pharma wins ANDA approval for generic sugammadex sodium injection
Monday, July 27
Champions Oncology posts record $59.4 million fiscal 2026 revenue
The oncology research company reported four straight quarters of positive adjusted EBITDA and continued investment in radiopharmaceuticals and its data platform.
SEC filing
CAMP4 gets Australian clearance to start CMP-002 trial in SYNGAP1 disorder
The clearance also triggers a second $50 million financing tranche tied to a September 2025 private placement, with closing expected August 3, 2026.
SEC filing
Gossamer Bio reacquires worldwide seralutinib rights from Chiesi, targets September NDA
Gossamer said an FDA Pre-NDA meeting supports filing seralutinib for PAH in September 2026, after ending its collaboration with Chiesi.
SEC filing